FGFR3 and urothelial carcinoma: Loriot et al9,10 led phase II and phase III trials (BLC2001) assessing erdafitinib in patients with metastatic or unresectable, locally advanced urothelial carcinoma that progressed after chemotherapy.11 Patients included in the studies had select FGFR3 mutation or FGFR2/3 fusion.